title: [Treatment of malignant effusions with the injection of dendritic cells derived from autologous peripheral CD34+ stem cells].
abstract: OBJECTIVE
  To evaluate the effect and side effects of CD34+ originated dendritic cells (DCs) infusion to treat malignant effusions.
  
  
  METHODS
  Twenty-three patients with 26 malignant effusions received chemotherapy and granulocyte colony-stimulating factor (G-CSF) or G-CSF alone to mobilize peripheral blood hematopoietic stem cells. CD34+ stem cells were induced to differentiate into DCs by cytokines interleukin 4 (IL-4), granulocyte-macrophage colony stimulating factor (GM-CSF), and tumor necrosis factor-alpha (TNF-alpha). After being cultured for 10 to 14 days to stimulate proliferation and grow mature, DCs were refused into the body cavity by drainage tube weekly for 3 weeks.
  
  
  RESULTS
  The response rate was 54% (14/26) and the benefit rate 81%. The median duration of response was 20 weeks (range:4-45 weeks). Karnofsky performance score (KPS) was improved in 15 patients. The response rate was 50% for the naive patients and 57% for the refractory patients. There were no severe side-effects.
  
  
  CONCLUSIONS
  This pilot study demonstrates that DCs derived in vitro can exist viably after intropleural injection and can mediate biologic activity to malignant effusions. DCs immunotherapy is promising to treat malignant effusions with good tolerance.
authors.affiliation: Department of Medical Oncology, Beijing Cancer Hospital & Institute, Peking University School of Oncology, Beijing 100142, China.
authors.forename: Li-jun
authors.initials: LJ
authors.lastname: Di
authors.forename: Jun
authors.initials: J
authors.lastname: Ren
authors.forename: Guo-hong
authors.initials: GH
authors.lastname: Song
authors.forename: Jing
authors.initials: J
authors.lastname: Yu
authors.forename: Jian
authors.initials: J
authors.lastname: Fang
authors.forename: Li
authors.initials: L
authors.lastname: Che
authors.forename: Yu-lin
authors.initials: YL
authors.lastname: Zhu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018952:Antigens, CD34 / Q000378:metabolism*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000150:complications; D002454:Cell Differentiation / Q000502:physiology; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000166:cytology / Q000637:transplantation*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D016066:Pleural Effusion, Malignant / Q000209:etiology / Q000628:therapy*; D011994:Recombinant Proteins
chemical_list: D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor